Use of Acid-Suppressive Drugs and Risk of Fracture: A Meta-analysis of Observational Studies

Chun-Sick Eom; Sang Min Park; Seung-Kwon Myung; Jae Moon Yun; Jeong-Soo Ahn

doi:10.1370/afm.1243

Published eLetters

If you would like to comment on this article, click on Submit a Response to This article, below. We welcome your input.

Submit a Response to This Article

Compose eLetter

Title *

Author Information

Contributors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Statement of Competing Interests

Competing interests? *

Yes

Please describe the competing interests

Vertical Tabs

Jump to comment:

Author response: Re: Why was our manuscript not included in this meta-analysis?
Sang Min Park

Published on: 13 May 2011
Why was our manuscript not included in this meta-analysis?
Frank de Vries

Published on: 12 May 2011

Published on: (13 May 2011)
Page navigation anchor for Author response: Re: Why was our manuscript not included in this meta-analysis?
Author response: Re: Why was our manuscript not included in this meta-analysis?
Sang Min Park, Seoul, Korea
Other Contributors:
Dear editor,
The de Vries et al study, entitled "Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates", reported adjusted relative rate using acid suppressive drugs (proton pump inhibitors or histamine2 receptor antagonists) with current vs. past user as comparator.
However our study inclusion criteria was outcome reported with the adjusted...
Show More

Dear editor,
The de Vries et al study, entitled "Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates", reported adjusted relative rate using acid suppressive drugs (proton pump inhibitors or histamine2 receptor antagonists) with current vs. past user as comparator.
However our study inclusion criteria was outcome reported with the adjusted odds ratio or relative risk using acid suppressive drugs (proton pump inhibitors or histamine2 receptor antagonists) with user vs. non-user as comparator, though we did not represent it explicitly in the methods section of our study.
The comparator not being clearly stated in the methods section was our mistake. In this sense we apologize, Dr. de Vries.
Best regards, Sang Min Park, Chun-Sick Eom, Seung-Kwon Myung, Jae Moon Yun, and Jeong-Soo Ahn
Competing interests: None declared
Show Less

Competing Interests: None declared.
Published on: (12 May 2011)
Page navigation anchor for Why was our manuscript not included in this meta-analysis?
Why was our manuscript not included in this meta-analysis?
Frank de Vries, Utrecht, Netherlands
Dear editor,
In their meta-analysis [1], Eom et al. have not included our manuscript entitled "Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates", which has been published in the December 2009 issue of Osteoporosis International [2]. Today (11 May 2011), I have replicated the search strategy as described by the authors, and our manuscript (PubMed ID 193...
Show More

Dear editor,
In their meta-analysis [1], Eom et al. have not included our manuscript entitled "Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates", which has been published in the December 2009 issue of Osteoporosis International [2]. Today (11 May 2011), I have replicated the search strategy as described by the authors, and our manuscript (PubMed ID 19333676) just showed up in the medline database. The paper does not meet any of the exclusion criteria, as stated in the methods section of the meta-analysis. Intriguingly, the US Food and Drug Administration has done the same when they conducted their literature review, in order to support the label change of PPIs in North-America last year. On 19 June 2010, we have highlighted this in a letter in osteoporosis international [3]. This letter also shows up in PubMed, when the search string by Eom et al. [1] is being executed.
References [1] Eom CS, Park SM, Myung SK, Yun JM, Ahn JS. Use of Acid-Suppressive Drugs and Risk of Fracture: A Meta-analysis of Observational Studies. Ann Fam Med. 2011 May-Jun;9(3):257-67. [2] de Vries F, Cooper AL, Cockle SM, van Staa TP, Cooper C. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int. 2009;20(12):1989-98. Epub 2009 Mar 31. [3] de Vries F, van Staa TP, Leufkens HG. Proton pump inhibitors, fracture risk and selection bias: three studies, same database, two answers. Osteoporos Int. 2011 May;22(5):1641-2. Epub 2010 Jun 19.
Competing interests: The Department of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, employing author Frank de Vries, has received unrestricted funding for pharmacoepidemiological research from GlaxoSmithKline, Novo Nordisk, the private-public funded Top Institute Pharma (www.tipharma.nl, includes co-funding from universities, government, and industry), the Dutch Medicines Evaluation Board, and the Dutch Ministry of Health.
Show Less

Competing Interests: None declared.